2 Bridge and Inovigate are proud to announce a strategic collaboration to provide fully integrated solutions in healthcare product development. The combined strength of our services go from drug development strategy over due diligence and opportunity scouting to product development, strategy and business planning – Matching the Target Product Profile with the Target Market Profile. Our joined customer portfolio ranges from the academic research over small and medium-sized biotech and medical device companies to large pharmaceutical enterprises and investors. Our teams take pride in delivering value while meeting high quality & reliable standards. We actively seek for cost-effective solutions in a global changing market.
Ingrid Maes, Managing Director Inovigate Benelux: “Through our integrated service offering and shared values of entrepreneurial and personal commitment we support entrepreneurs in bringing innovation to life.”
Ann Meulemans, Managing Director 2 Bridge: “We share the same ambition to shape the healthcare eco-system into an environment that adds value to all – from entrepreneurs to society to patients”.
Inovigate is an independent specialised European consultancy firm operating in the Pharma, Med Tech and Life Science community. We guide our clients through the complex strategic and financial challenges that they face during each stage of their projects, from discovery to market entry, from acquisition of a target to an equity issuance process and merger.
Inovigate supports scientists and entrepreneurs to accelerate, professionalize and fund life science innovations and successfully build a new business in an increasingly complex health care environment.
2 Bridge is a Belgian company that provides strategic & scientific support, project leadership and due diligence services for pharmaceutical and health product development, and production. The 2 Bridge team offers multi-disciplinary services in drug discovery, pre-clinical, CM&C and clinical development, registration and post-approval support, as well as trainings. We guide our clients to through the complex challenges they face during drug development.
Through our in-depth drug development, sector and financial expertise combined with our extensive network in the health sector, academic institutes and investor community, we support our clients to unlock the maximum value out of their projects. Our ultimate goal is to improve health outcomes, efficiency and well-being by facilitating successful introduction of patient-centered health solutions.